

**ALLIANCE AGAINST CANCER
6TH ANNUAL MEETING**

**NEW TECHNOLOGIES
AND STRATEGIES
TO FIGHT CANCER**



Host
institution



SEPTEMBER 23-25, 2021



Patronage
Required



Rete AMORE
partners



9.00

Welcome addresses

A. Paradiso, *Bari* - R. De Maria, *Roma* - A. Delle Donne, *Bari* - N. Normanno, *Napoli*
A. Sgambato, *Rionero in Vulture* - G. Ippolito, *Roma* - M. Emiliano, *Bari*

OPENING SESSION

9.30

Opening

G. Guglielmi, *Roma* - G. Scalera, *Roma*

Lecture

Trends in modern Phase I Oncology Trials

G. Curigliano, *Milano*

Introduction - P.F. Conte, *Padova*

Session 1 - Cancerogenesis and disease progression

CHAIRMEN | A. Mantovani, *Milano* - A. Moschetta, *Bari*

10.00

Myeloid cells in cancer

M. Merad, *New York*

10.20

The BAP1 cancer syndrome and the overall significance of GXE interaction in mesothelioma

M. Carbone, *Honolulu*

10.40

Selected presentations

Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression

E. Magrini, *Milano*

Role of quiescence in Acute Myeloid Leukemia growth

C. Restelli, *Milano*

LXR α identifies pro-inflammatory macrophages, predicts survival and provides a therapeutic rationale in DLBCL

M.C. Vegliante, *Bari*

Liquid biopsy for molecular characterization and for monitoring of drug response in metastatic colorectal cancers

M. Urbini, *Meldola - Forlì*

11.20

Discussion and Posters review

Session 2 - New Insights in microorganism and cancer

CHAIRMEN | M. Tommasino, *Lyon* - M. Rescigno, *Milano*

11.40

Virus and Cancer

T. Schulz, *Hannover*

12.00

Microbiota in cancer progression and metastasis

M. Rescigno, *Milano*

12.20

Selected presentations

Body fluids biomarkers for head and neck cancer prevention/early diagnosis

S. Chiocca, *Milano*

Evaluation and associations of dietary habits, the metabolome, microbiome and immune profile in patients diagnosed with bone sarcoma. A case control study

A. Longhi, *Bologna*

12.40

Discussion and Posters review

13.00 - 14.00

Posters viewing

Session 3 - COVID 19 and Cancer

CHAIRMEN | G. Apolone, Milano - G. Ciliberto, Roma

14.00 **Adaptive immune response after COVID-19 vaccination in cancer patients: THE CAPTURE study**

A. Fendler, London

14.20 **COVID vaccination in Cancer patient**

M.C. Garassino, Milano/Chicago

14.40 **Selected presentations**

Reactive Axillary Lymph nodes to COVID-19 Vaccination on F18FDG, F18Choline and Ga68DOTATOC PET/CT in Cancer Patients

A. Giordano, *Rionero in Vulture*

Real-world data confirm that tamoxifen treatment protects breast cancer patients from COVID-19

S. Bravaccini, *Meldola - Forlì*

15.00 Discussion and Posters review

Session 4 - From population to genetics to cancer

CHAIRMEN | S. Franceschi, Aviano - S. Tommasi, Bari

15.30 **Risk adapted screening and prevention of breast cancer**

J. Cuzick, London

15.50 **Osteosarcoma epidemiology and genetic susceptibility: connecting etiology, biology, and treatment**

L. Mirabello, Bethesda

16.10

Selected presentations

Analysis of genomic data reported in the Italian Register of Actionable Mutations (RATIONAL) clinical trial

E.A. Riziero, *Napoli*

A Mediterranean dietary intervention in women carriers of BRCA mutations

P. Pasanisi, *Milano*

16.30

Discussion and Posters review

Session 5 - ACC strategic-projects update

CHAIRMEN | P.G. Pelicci, Milano - N. Normanno, Napoli

17.00

The ACC Lung-cancer project

V. Gregorc, *Milano*

17.20

Gersom: The new paradigm in clinical cancer genomics

D. Lorusso, *Roma*

17.40

Health Big Data: Update on the Health Big Data project

P. Locatelli, *Milano*

18.00

Digicore

G. Ciliberto, *Roma*

18.20

Forza: The ACC Clinical-Research Infrastructure

S. Pignata, *Napoli*

18.40

Discussion

20.30

Social Event

Santa Scolastica Museum guided tour

Drinks & Foods

Session 6 - New Insights in Immunotherapy

CHAIRMEN | P. Ascierto, Napoli - M. Guida, Bari

9.30 **What we learned from immunotherapy in the past years**

P. Ascierto, Napoli

9.50 **Neoadjuvant treatments with checkpoints inhibitors**

C. Blank, Amsterdam

10.10 **Selected presentations**

Results of the therapeutic cancer vaccine HepaVac-101 clinical trial in HCC patients

L. Buonaguro, Napoli

Patient-derived melanoma 3D explants as preclinical model to test local immunomodulation after immunotherapy

E. Vergani, Milano

10.30 Discussion and Posters review

10.50 *Slot Sponsor Speech - no ecm*

From target discovery to validation of therapeutic compounds with new cutting-edge technologies

Speaker: Dario Leone - Application Specialist Miltenyi Biotec



Session 7 - Where we are with CAR-T cells

CHAIRMEN | A. Pinto, Napoli - G. Martinelli, Meldola-Forlì

11.10 **CAR-T cells: the next challenges for the future**

F. Locatelli, Roma

11.30 Preclinical development of new CAR-T cells

F. Ciceri, Milano

11.50 Selected presentations

Machine learning-assisted analysis identifies MRC2 (ENDO180) as promising stromal target for CAR-T therapy in NSCLC

G. Toietta, Roma

Tumor induced myeloid-derived suppressor cells impair the response to GD2-CAR T cells in xenograft models of osteosarcoma

B. De Angelis, Roma

12.10 Discussion and Posters review

12.30 Slot Sponsor Speech - no ecm

Where we are with CAR-T cells... and where are we going

Speaker: Concetta Quintarelli, Roma



13.00 - 14.00

Poster viewing

Session 8 - Digital pathology in clinical and research practice

CHAIRMEN | F. Fraggetta, Catania - A. Sgambato, Rionero in Vulture

14.00 Digital Pathology: an opportunity not to be missed

F. Fraggetta, Catania

14.20 AI in Digital Pathology: from research to clinics

M. Atzori, Sierre

14.40

Selected presentations

Can Generative Adversarial Networks Mitigate the Impact of Small Sample Size in Digital Pathology Setups?

N. Altini, *Bari*

Bridging the Gap between Digital Pathology and Molecular Biology: Predicting KRAS Alteration from Whole Slide Images.

S. De Summa, *Bari*

15.00

Discussion and Posters review

Session 9 - Functional and clinical imaging

CHAIRMEN | L. Boldrini, Roma - R. Bellotti, Bari

15.20

Features standardization: the IBSI initiative

A. Zwanenburg, *Dresden*

15.40

Radiomics research for clinical translation

N. Papanikolaou, *Lisboa*

16.00

Selected presentations

A Multi-Centre Evaluation of Dosimetrics Features Reproducibility, Stability and Sensitivity

L. Placidi, *Roma*

FDG PET/CT imaging and radiomics as predictors of early response in lymphoma patients undergoing CAR T-cell therapy

S. Fanti, *Bologna*

16.20

Discussion and Posters review

Session 10 - Cancer burden, finance, and health-care systems

CHAIRMEN | A. Guarini, Bari - F. De Lorenzo, Roma - N. Silvestris, Bari

- 16.40** **Out-of-pocket costs sustained by Italian cancer patients in 2016-18**
F. De Lorenzo, Roma
- 17.00** **The activities of OECI WG Health Economics and benchmarking**
V. Retel, Amsterdam
- 17.20** **New in vitro diagnostic regulation (IVDR) between NGS and LDT assays**
G. Codacci Pisanelli, Roma
- 17.40** **Selected presentations**
A novel index to measure geographical accessibility to cancer clinical trials in different income landscapes
G. Tini, Milano
The ACC-GDPR Committee guidelines:
A template for the implementation of the EU GDPR for Italian research hospitals
L. Marelli, Milano
- 18.00** Discussion and Posters review

18.30

Board of ACC Directors

20.15

ACC Assembly

21.15

Dinner for the ACC board

Session 11 – WG reports and programs

CHAIRMEN | P. De Paoli, Roma - M. Alcalay, Milano

9.00

Working Groups:

1) WG activity and new projects 2021

P.G. Pelicci, Milano

2) Melanoma

G. Russo, Roma

3) Genomics

L. Mazzaella, Milano

4) Radiomics

L. Boldrini, Roma

10.15

Discussion

10.30

Coffee Break

Round Table: National Cancer Research Strategies

CHAIRMEN | R. De Maria, Roma - A. Paradiso, Bari

10.50

Scheduled Speeches:

AIOM

S. Cinieri, Brindisi

SIAPEC

A. Sapino, Candiolo

SIGU-SEGU

M. Genuardi, Roma

GIMEMA

M. Vignetti, Roma

SIMeP

P. Marchetti, Roma

Rete Tumori Rari

P. Casali, Milano

Discussion

12.15

ACC strategies

P.G. Pelicci, Milano

12.45

Poster Awards

Presented by P. Pronzato, Genova

12.50

Concluding remarks and Recommendations

R. De Maria, Roma - A. Paradiso, Bari

Faculty

Alcalay	Myriam	Istituto Europeo di Oncologia - Milano
Altini	Nicola	Politecnico di Bari
Apolone	Giovanni	Fondazione IRCCS - Istituto Nazionale dei Tumori - Milano
Ascierto	Paolo Antonio	IRCCS Istituto Nazionale Tumori - Fondazione G. Pascale - Napoli
Atzori	Manfredo	"HES-SO Valais" - University of Applied Sciences Western Switzerland - Sierre
Bellotti	Roberto	Università degli studi di Bari "Aldo Moro" - Bari
Blank	Christian	Netherlands Cancer Institute - Amsterdam
Boldrini	Luca	Fondazione Policlinico Universitario - A. Gemelli IRCCS - Roma
Bravaccini	Sara	IRCCS Istituto Romagnolo per lo Studio dei Tumori - "Dino Amadori" - Meldola
Buonaguro	Luigi	IRCCS Istituto Nazionale Tumori - Fondazione G. Pascale - Napoli
Carbone	Michele	University of Hawaii Cancer Center - Honolulu
Casali	Paolo	Fondazione IRCCS - Istituto Nazionale dei Tumori - Milano
Chiocca	Susanna	Istituto Europeo di Oncologia - Milano
Ciceri	Fabio	IRCCS Ospedale San Raffaele - Milano
Ciliberto	Gennaro	IRCCS Istituto Nazionale Tumori Regina Elena - Roma
Cinieri	Saverio	Ospedale "A. Perrino" - Brindisi
Codacci Pisanelli	Giovanni	Università degli Studi di Roma "Sapienza" - Roma
Conte	Pierfranco	IRCCS - Istituto Oncologico Veneto - Padova
Curigliano	Giuseppe	Istituto Europeo di Oncologia - Milano
Cuzick	Jack	Queen Mary University of London
De Angelis	Biagio	IRCCS Ospedale Pediatrico Bambino Gesù - Roma
De Lorenzo	Francesco	Federazione Italiana delle Associazioni di Volontariato in Oncologia - Roma
De Maria	Ruggero	Università Cattolica del Sacro Cuore - Roma
De Paoli	Paolo	Centro di Riferimento Oncologico di Aviano - Aviano
De Summa	Simona	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
Delle Donne	Alessandro	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
Emiliano	Michele	Giunta Regionale della Puglia

Faculty

Esposito Abate	Riziero	IRCCS Istituto Nazionale Tumori - Fondazione G. Pascale - Napoli
Fanti	Stefano	IRCCS Azienda Ospedaliero Universitaria di Bologna
Fendler	Annika	The Francis Crick Institute - London
Fraggetta	Filippo	Azienda Ospedaliera per l'Emergenza Cannizzaro - Catania
Franceschi	Silvia	Centro di Riferimento Oncologico di Aviano - Aviano
Garassino	Marina Chiara	Fondazione IRCCS - Istituto Nazionale dei Tumori - Milano
Genuardi	Maurizio	Fondazione Policlinico Universitario A. Gemelli IRCCS - Roma
Giordano	Alessia	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
Gregorc	Vanesa	IRCCS Ospedale San Raffaele - Milano
Guarini	Attilio	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
Guglielmi	Gaetano	Ministero della Salute - Roma
Guida	Michele	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
Ippolito	Giuseppe	Ministero della Salute - Roma
Locatelli	Franco	IRCCS Ospedale Pediatrico Bambino Gesù - Roma
Locatelli	Paolo Romolo	Politecnico di Milano
Longhi	Alessandra	Istituto Ortopedico Rizzoli - Bologna
Lorusso	Domenica	Fondazione Policlinico Universitario A. Gemelli IRCCS - Roma
Magrini	Elena	IRCCS Humanitas Research Hospital - Milano
Mantovani	Alberto	IRCCS Humanitas Research Hospital - Milano
Marchetti	Paolo	Azienda Ospedaliero-Universitaria Sant'Andrea - Roma
Marelli	Luca	Istituto Europeo di Oncologia - Milano
Martinelli	Giovanni	IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - Meldola
Mazzarella	Luca	Istituto Europeo di Oncologia - Milano
Merad	Miriam	Icahn School of Medicine at Mount Sinai - New York
Mirabello	Lisa	Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH - Bethesda
Moschetta	Antonio	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
Normanno	Nicola	IRCCS Istituto Nazionale Tumori - Fondazione G. Pascale - Napoli

Faculty

Papanikolaou	Nickolas	Champalimaud Foundation - Lisboa - Portugal
Paradiso	Angelo Virgilio	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
Pasanisi	Patrizia	Fondazione IRCCS - Istituto Nazionale dei Tumori - Milano
Pelicci	Pier Giuseppe	Istituto Europeo di Oncologia - Milano
Pignata	Sandro	IRCCS Istituto Nazionale Tumori - Fondazione G. Pascale - Napoli
Pinto	Antonello	IRCCS Istituto Nazionale Tumori - Fondazione G. Pascale - Napoli
Placidi	Lorenzo	Fondazione Policlinico Universitario A. Gemelli IRCCS - Roma
Pronzato	Paolo	IRCCS Ospedale Policlinico San Martino - Genova
Rescigno	Maria	IRCCS Ospedale San Raffaele - Milano
Restelli	Cecilia	Istituto Europeo di Oncologia - Milano
Retel	Valesca	Netherlands Cancer Institute - Amsterdam
Russo	Giandomenico	IRCCS - Istituto Dermopatico dell'Immacolata - Roma
Sapino	Anna	IRCCS - Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - Candiolo
Scalera	Giselda	Ministero della Salute - Roma
Schulz	Thomas	Hochschule Hannover - Hannover
Sgambato	Alessandro	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
Silvestris	Nicola	Universita' degli Studi di Bari "Aldo Moro" - Bari
Tini	Giulia	Istituto Europeo di Oncologia - Milano
Toietta	Gabriele	IRCCS Istituto Nazionale Tumori Regina Elena - Roma
Tommasi	Stefania	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
Tommasino	Massimo	International Agency for Research on Cancer - Lyon
Urbini	Milena	IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - Meldola
Vegliante	Maria Carmela	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
Vergani	Elisabetta	Fondazione IRCCS - Istituto Nazionale dei Tumori - Milano
Vignetti	Marco	Università degli Studi di Roma "Sapienza" - Roma
Zwanenburg	Alexander	National Center for Tumor Diseases - Dresden

Committees

SCIENTIFIC COORDINATORS

ANGELO PARADISO

Istituto Tumori, "G. Paolo II", IRCCS-Bari, Italy

ALESSANDRO SGAMBATO

IRCCS CROB- Rionero in Vulture, Italy

NICOLA NORMANNO

Istituto Nazionale Tumori

Fondazione Pascale-IRCCS Napoli, Italy

ALLIANCE AGAINST CANCER

RUGGERO DE MARIA, *Roma*

PIERGIUSEPPE PELICCI, *Milano*

PAOLO DE PAOLI, *Roma*

RETE AMORE

ALESSANDRO DELLE DONNE, *Bari*

ATTILIO BIANCHI, *Napoli*

GERARDO DI MARTINO, *Rionero in Vulture*

MINISTRY OF HEALTH

GIOVANNI LEONARDI, *Rome*

GIUSEPPE IPPOLITO, *Rome*

GAETANO GUGLIELMI, *Rome*

NOVELLA LUCIANI, *Rome*

GISELDA SCALERA, *Rome*

SCIENTIFIC COMMITTEE

GIOVANNI APOLONE, *Milano*

GENNARO CILIBERTO, *Roma*

SILVIA FRANCESCHI, *Aviano*

GIOVANNI MARTINELLI, *Meldola-Forlì*

PIERGIUSEPPE PELICCI, *Milano*

ANTONIO UCCELLI, *Genova*

PIERFRANCO CONTE, *Padova*

MASSIMO COSTANTINI, *Reggio Emilia*

ROBERTO ORECCHIA, *Milano*

FABIO CICERI, *Milano*

ALBERTO MANTOVANI, *Milano*

GIUSEPPE REMUZZI, *Milano*

PAOLO MARCHETTI, *Roma*

ANNA SAPINO, *Candiolo*

ORGANIZING COMMITTEE

CLAUDIA MORETTI, *Bari*

SILVANA VALERIO, *Bari*

ENRICA D'ACCIO, *Bari*

MASSIMO BONI, *Roma*

dirscientifica@oncologico.bari.it

press@alleanzacontroilcancro.it

LOCAL SCIENTIFIC COMMITTEE

STEFANIA TOMMASI, *Bari*

NICOLA SILVESTRIS, *Bari*

ATTILIO GUARINI, *Bari*

COSIMO GADALETA, *Bari*

ALFREDO ZITO, *Bari*

MICHELE SIMONE, *Bari*

LORETO GESUALDO, *Bari*

ANGELO VACCA, *Bari*

ROBERTO BELLOTTI, *Bari*

ANTONIO MOSCHETTA, *Bari*

CAMILLO PORTA, *Bari*

NICOLA NORMANNO, *Napoli*

SANDRO PIGNATA, *Napoli*

PAOLO ASCIERTO, *Napoli*

ALFREDO BUDILLON, *Napoli*

FRANCO PERRONE, *Napoli*

PAOLO DELRIO, *Napoli*

ANTONELLA PETRILLO, *Napoli*

ANNAROSARIA DE CHIARA, *Napoli*

GIUSEPPE PIETRANTUONO, *Rionero in Vulture*

GIOVANNI BOZZA, *Rionero in Vulture*

GIOVANNI STORTO, *Rionero in Vulture*

DARIO SCALA, *Rionero in Vulture*

VALENTINA CONDELLI, *Rionero in Vulture*

ALFREDO TARTARONE, *Rionero in Vulture*

RAFFAELE CONCA, *Rionero in Vulture*

MICHELE AIETA, *Rionero in Vulture*

ORGANIZING SECRETARIAT

CIC SUD - CENTRO ITALIANO CONGRESSI

Viale Escrivè n° 28 - 70124 - Bari

Tel. 080/5043737 - Fax 080/5043736

info@cicsud.it - www.cicsud.it



2021

Submitted Abstracts

ABSTRACT_1_Cancerogenesis and disease progression

CRISPO FABIANA	Regulation of epigenetic rewiring in neoplastic cells	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
COSTANZA BRUNELLA	Metabolic Plasticity drives intrinsic resistance toward anti-LSD1 therapy in GBM	Istituto Europeo di Oncologia - Milano
ERRANI COSTANTINO	The prognostic value of serum inflammatory biomarkers in pediatric Ewing's sarcoma	Istituto Ortopedico Rizzoli - Bologna
BREVI ARIANNA	Castration-related remodeling of the tumor microenvironment supports the progression to neuroendocrine prostate cancer	IRCCS Ospedale San Raffaele - Milano
CARDINALI BARBARA	The NEOGENE trial Update: Genomic test aiming to identify actionable mutations in Hormone Receptor -/ HER2+ or triple negative breast cancer	IRCCS Ospedale Policlinico San Martino - Genova
CARDINALI BARBARA	Targeting PIK3CA actionable mutations in the circulome: a proof of concept in metastatic breast cancer	IRCCS Ospedale Policlinico San Martino - Genova
DELLINO GAETANO IVAN	Role of DNA repeats in the organization of chromatin topology and global changes of gene expression in APL cells	Istituto Europeo di Oncologia - Milano
RIZZO RICCARDO	From GOLPH3 mediated oncogenesis to pH mapping in complex 3D tumor systems: advanced tools towards precision medicine	Institute of Nanotechnology CNR NANOTEC - Lecce
PORTELLA LUIGI	CXCL12-loaded-hydrogel as a new tool for CTCs capturing and characterization: the TRAP4MET clinical trial experience	IRCCS Istituto Nazionale Tumori Fondazione G. Pascale - Napoli
RAVAIOLI SARA	The unfavorable prognostic role of HDAC6 in trastuzumab resistance of HER2-positive breast cancer patients	IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - Meldola
RESELLI CECILIA	Role of quiescence in Acute Myeloid Leukemia growth	Istituto Europeo di Oncologia - Milano
RINALDI FEDERICA	A circulating miRNA signature as a predictor of outcome and therapy response in diffuse large B-cell lymphoma patients	IRCCS Istituto Nazionale Tumori Regina Elena - Roma
RUBBINO FEDERICA	HFE H63D variant promotes EMT of pancreatic cancer in a cell-cycle dependent manner and through perineuronal invasion	IRCCS Humanitas Research Hospital - Milano
VOLPE GIACOMO	Ablation of MYB-dependent leukaemia phenotype in MLL-driven AML correlates with increased expression of MAFB	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
VANNINI IVAN	Identification of Predictive Factors in Advanced Pancreatic Cancer Through Extracellular Vesicle Analysis	IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - Meldola

Submitted Abstracts

TOGO GIULIA	Pre-treatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as predictors of occult cervical metastasis in clinically negative neck supraglottic and glottic cancer.	Università degli Studi di Napoli Federico II - Napoli
URBINI MILENA	Liquid biopsy for molecular characterization and for monitoring of drug response in metastatic colorectal cancers	IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - Meldola
DE VITA ALESSANDRO	Tumor microenvironment fingerprinting in liposarcoma landscape as a guide for chemotherapy decision: preclinical evidences	IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - Meldola
DIAZ MENDEZ ANA BELEN	A diagnostic and monitoring circulating miRNA signature impacts glioma biology	IRCCS Istituto Nazionale Tumori Regina Elena - Roma
DERAKHSHANI AFSHIN	A weighted gene co-expression network analysis uncovers shared and distinct pathways in inflammatory bowel disease and colorectal cancer	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
GHELLI LUSERNA DI RORA' ANDREA	Modulate autophagy to target acute lymphoblastic leukemia cells	IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - Meldola
GHELLI LUSERNA DI RORA' ANDREA	The prolonged pharmacological inhibition of chk1/chk2 kinases modifies the efficacy of different dna damaging agents against acute lymphoblastic leukemia cells	IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - Meldola
FORMENTINI LAURA	Precision medicine in osteosarcoma: the value of representative models	Istituto Ortopedico Rizzoli - Bologna
GARZARELLI VALERIA	Human Prostate cancer On Chip: an innovative investigative approach	Institute of Nanotechnology CNR NANOTEC - Lecce
MAZZOCCOLI CARMELA	BIOLOGICAL Effects of N-acetylaspartate (NAA) in BX-PC3 PANCREATIC Cancer Cell Line Using 2D and 3D Cultures	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
RONCHETTI LIVIA	Evaluation of NETosis features for non-invasive endometrial cancer stratification	IRCCS Istituto Nazionale Tumori Regina Elena - Roma
PERRONE CLARA	SMOX induction sensitizes Fusion-Negative Rhabdomyosarcoma cells to radiation	IRCCS Ospedale Pediatrico Bambino Gesù - Roma
NOTARANGELO TIZIANA	STAT3 mediates resistance to cisplatin in gastric cancer	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
PADELLA ANTONELLA	Genomic and transcriptomic profiles of acute myeloid leukemia patients reveal associations between known genes mutations and DNA damage response alterations	IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - Meldola
RUSSI SABINO	TRPV2 cationic channel as potential target to overcome cisplatin-induced apoptosis resistance in gastric cancer	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture

Submitted Abstracts

PIASTRA VALENTINA	MKK3/AURKA crosstalk fosters malignancy in colorectal cancer: implications for novel therapeutic approaches	IRCCS Istituto Nazionale Tumori Regina Elena - Roma
PAGGI MARCO GIORGIO	Chlorpromazine induces cytotoxic autophagy in glioblastoma cells via endoplasmic reticulum stress and unfolded protein response	IRCCS Istituto Nazionale Tumori Regina Elena - Roma
PRANTEDA ANGELINA	THE MKK3-c-MYC AXIS SUSTAINS DABRAFENIB RESISTANCE IN COLORECTAL CARCINOMA	IRCCS Istituto Nazionale Tumori Regina Elena - Roma
NACCHIA ANTONIO	Serum levels of chromogranin are not predictive of poorly differentiated prostate cancer: results from a multicenter radical prostatectomy cohort	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
NACCHIA ANTONIO	Role of inflammatory markers and frailty index as predictors of adverse pathological stage and complications in patients with upper urinary tract urothelial cancer: a multicenter analysis	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
NACCHIA ANTONIO	Role of inflammatory markers as predictors of adverse pathological outcomes in patients with testicular cancer: a multicenter analysis	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
DI FONTE ROBERTA	Patient-derived organotypic tumor cultures of metastatic melanoma for personalised therapeutic screening	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
PELLIZZARI LUCA	Analysis of Next Generation Sequencing (NGS) data of circulating tumor DNA (ctDNA) by Variant Calling comparison and database integration of VCF files	Centro di Riferimento Oncologico di Aviano - Aviano
STATUTO TEODORA	Assessment of nk cell subpopulations levels and cytotoxic activity in hematologic malignancies	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
VEGLIANTE MARIA CARMELA	LXR α identifies pro-inflammatory macrophages, predicts survival and provides a therapeutic rationale in DLBCL	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
DAURIA FIORELLA	Effects of pelvis radiotherapy on peripheral lymphocyte subpopulations in prostate cancer patients	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
NACCHIA ANTONIO	Serum levels of sex hormone binding globulin are not predictive of poorly differentiated prostate cancer or advanced prostate cancer: results from a radical prostatectomy cohort	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
NACCHIA ANTONIO	Urotensin II receptor expression in prostate cancer patients: a new possible marker	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
BARBIERI ANTONIO	β 2-AR blockade potentiates MEK1/2 inhibitor effect on HNSCC by regulating the Nrf2-mediated defense mechanism	IRCCS Istituto Nazionale Tumori Fondazione G. Pascale - Napoli
LAURENZANA ILARIA	Multiple Myeloma Extracellular Vesicles Impair Normal Hematopoiesis Acting On Hematopoietic Stem/Progenitor Cells	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture

Submitted Abstracts

LAURINO SIMONA	CHIR99021 promotes autophagic cell death consequent to G2/M arrest and mitotic catastrophe in epithelioid sarcoma cells	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
LOVATI GIULIA	3D Organotypic Melanoma Model: a Potent Tool to Dissect the Influence of Tumor Microenvironment in Melanoma Progression	Istituto Europeo di Oncologia - Milano
LUCCHETTI DONATELLA	EVs released by differentiating colorectal cancer stem cells induces a switch from oxidative to glycolytic metabolism in cancer-associated fibroblasts	Istituto di Patologia Generale, Università Cattolica del Sacro Cuore di Romaerale - Roma
LUGINI LUANA	Disease stage definition by fatty acid and proteomic profile of CD81+small extracellular vesicles in melanoma patients	Istituto Superiore di Sanità - Roma
MAGRINI ELENA	Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression	IRCCS Humanitas Research Hospital - Milano
MARCHINI SERGIO	Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated to prognosis	IRCCS Humanitas Research Hospital - Milano

ABSTRACT_2_New Insights in microorganism and cancer

LONGHI ALESSANDRA	Evaluation and associations of dietary habits, the metabolome, microbiome and immune profile in patients diagnosed with bone sarcoma. A case control study	Istituto Ortopedico Rizzoli - Bologna
PIRINI FRANCESCA	Exploring the functional role of breast cancer tissue microbiota by a multi-omic approach	IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - Meldola
CHIOCCA SUSANNA	Body fluids biomarkers for head and neck cancer prevention/early diagnosis	Istituto Europeo di Oncologia - Milano
TAGLIAMONTE MARIA	Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs)	IRCCS Istituto Nazionale Tumori Fondazione G. Pascale - Napoli
GHIANI LAVINIA	Characterizing the Oncogenic role of the H3K36me2 Methyltransferase NSD2 in HPV+ and HPV- Head and Neck Cancer (HNC)	Istituto Europeo di Oncologia - Milano
BUQUICCHIO ROSALBA	Detection of beta HPVs in multiple biological specimens from patients with history of AK and cSCC lesions	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari

Submitted Abstracts

ABSTRACT_3_Covid-19 and cancer

BERRINI ROMANA	Covid-19 impact on the neuro-oncological population. Evaluation of criticality and resources of patients and caregivers	AITC - Associazione Italiana Tumori Cerebrali ONLUS - Milano
BRAVACCINI SARA	Real-world data confirm that tamoxifen treatment protects breast cancer patients from COVID-19	IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - Meldola
TORNESELLO MARIA LINA	Collection of head and neck cancer biological samples during SARS-CoV-2 pandemic: SOP developed by ACC HNC working group	IRCCS Istituto Nazionale Tumori Fondazione G. Pascale - Napoli
MAZZARELLA LUCA	Significantly lower probability of infections after Covid-19 vaccine than after natural infection	Istituto Europeo di Oncologia - Milano
GIORDANO ALESSIA	Reactive Axillary Lymph nodes to COVID-19 Vaccination on F18FDG, F18Choline and Ga68DOTATOC PET/CT in Cancer Patients	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
ROMANO OLGA	COVID-19 VACCINO VIGILANCE: FOCUS ON CANCER PATIENTS	Università degli Studi di Napoli Federico II - Napoli
SERAFINI ANTONIO	Soluzioni informatiche per superare le problematiche da Covid-19 nella gestione delle sperimentazioni cliniche	Fondazione IRCCS Istituto Nazionale dei Tumori - Milano

ABSTRACT_4_From population to genetics to cancer

PASANISI PATRIZIA	A Mediterranean dietary intervention in women carriers of BRCA mutations	Fondazione IRCCS Istituto Nazionale dei Tumori - Milano
BONETTI EMANUELE	The RENOVO dashboard, a new method of exploration and investigation of germline genetic variants	Istituto Europeo di Oncologia - Milano
ESPOSITO ABATE RIZIERO	Analysis of genomic data reported in the Italian Register of Actionable Mutations (RATIONAL) clinical trial	IRCCS Istituto Nazionale Tumori Fondazione G. Pascale - Napoli
PATRUNO MARGHERITA	Spectrum of germline pathogenic variants in BRCA1/2 genes in the Apulian southern Italy population: Geographic distribution and evidence for targeted genetic testing.	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
NACCHIA ANTONIO	Higher testosterone serum levels are associated with a higher childbirth in patients treated for testicular cancer	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
NACCHIA ANTONIO	The role of metabolic syndrome in high grade prostate cancer: development of a clinical nomogram	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture

Submitted Abstracts

VOZZA GIANLUCA	A novel computational tool to compare the performance of NGS panels and Variant Calling pipelines: RecallME	Istituto Europeo di Oncologia - Milano
NACCHIA ANTONIO	Metabolic Syndrome evaluation improves prostate cancer detection in patients undergoing a repeat biopsy	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
NACCHIA ANTONIO	Statin use is associated to an increased risk of prostate cancer diagnosis: an Italian biopsy cohort analysis	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
NACCHIA ANTONIO	Hypogonadism is associated with a reduced risk of high grade prostate cancer	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture

ABSTRACT_6_New insights in immunotherapy

GIUSEPPE MANCUSO	Novel Bioluminescent Bioassays for the Discovery and Development of T Cell Redirecting Cancer Therapies	Promega Italia S.R.L. - Milano
PINTO ROSAMARIA	Merkel cell carcinoma: insights into the tumor microenvironment and immunological genetic and expression pattern	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
SERRATI' SIMONA	Circulating extracellular vesicles: from immunosuppression to biomarkers for predicting response to anti-PD1 immunotherapy in metastatic melanoma	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
PEZZICOLI GAETANO	Tumor neoantigens shape the immune microenvironment of panNETs: an in silico analysis	Università degli studi di Bari "Aldo Moro" - Bari
QUINTARELLI CONCETTA	Donor T Cells Genetically Modified with a Novel Suicide Gene htCD19 to reduce GVHD post HSCT	IRCCS Ospedale Pediatrico Bambino Gesù - Roma
ARBORE GIUSEPPINA	Deciphering the immunological determinants of response to neoadjuvant chemo-radiation in esophageal adenocarcinoma	IRCCS Ospedale San Raffaele - Milano
MAZZA MASSIMILIANO	In situ BCR repertoire analysis allows for human NSCLC targeting antibodies identification	IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - Meldola
FILACI GILBERTO	Telomerase-based GX301 cancer vaccine in patients with metastatic prostate cancer: a randomized phase II trial	Università degli Studi di Genova
MELCHIONNA ROBERTA	The actin regulator hMENA modulates TGF- β signaling, CAFs/cancer cells cross-talk and immunosuppression in NSCLC	IRCCS Istituto Nazionale Tumori Regina Elena - Roma
CARRIERO MARIA VINCENZA	Crosstalk between macrophages and myxoid liposarcoma cells increases spreading and invasiveness of tumor cells	IRCCS Istituto Nazionale Tumori Fondazione G. Pascale - Napoli

Submitted Abstracts

VERGANI ELISABETTA	Patient-derived melanoma 3D explants as preclinical model to test local immunomodulation after immunotherapy	Fondazione IRCCS Istituto Nazionale dei Tumori - Milano
NACCHIA ANTONIO	Safety evaluation of sequential Mitomycin and Bacillus Calmette-Guérin treatment versus Bacillus Calmette-Guérin monotherapy in patients with High risk Non-Muscle Invasive Bladder Cancer: MITOBCG study (EUDRACT Number 2017-004540-37) preliminary results	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
NACCHIA ANTONIO	Inflammatory Markers Role in patients affected by urological cancers treated by surgery (IRU Study Project)	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
NACCHIA ANTONIO	Role of inflammatory markers and frailty as predictors of adverse pathological stage and complications in patients undergoing renal cancer surgery: a multicenter analysis	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
BUONAGURO LUIGI	Results of the therapeutic cancer vaccine HepaVac-101 clinical trial in HCC patients	IRCCS Istituto Nazionale Tumori Fondazione G. Pascale - Napoli

ABSTRACT_7_Where we are with Car-T cells

ZINZANI PIER	Car-t cell therapy in aggressive lymphomas: the real life experience of "I. E a. Seràgnoli" institute of bologna	IRCCS Azienda Ospedaliero- Universitaria di Bologna
DE ANGELIS BIAGIO	Tumor induced myeloid-derived suppressor cells impair the response to GD2-CAR T cells in xenograft models of osteosarcoma	IRCCS Ospedale Pediatrico Bambino Gesù - Roma
CARUSO SIMONA	CAR-NK cells display strong antitumor activity against CD123+ leukaemia stem cells from Acute Myeloid Leukaemia patients	IRCCS Ospedale Pediatrico Bambino Gesù - Roma
CHIRIACO' MARIA SERENA	Polymeric and three-dimensional biochips for biological investigations through microfluidics: TITAN Project insights	Institute of Nanotechnology CNR NANOTEC - Lecce
PALAMA' ILARIA ELENA	Non-viral responsive nanovectors for CAR-T cell production	Institute of Nanotechnology CNR NANOTEC - Lecce
GUIDONI FRANCESCO	Car-T: una nuova possibilità nel trattamento del mieloma multiplo	Fondazione IRCCS Istituto Nazionale dei Tumori - Milano
CICCONE ROSELIA	Bispecific CAR (Bi.CAR) targeting both GD2 and B7H3 as an innovative and powerful adoptive T cell therapy for sarcoma	IRCCS Ospedale Pediatrico Bambino Gesù - Roma
TOIETTA GABRIELE	Machine learning-assisted analysis identifies MRC2 (ENDO180) as promising stromal target for CAR-T therapy in NSCLC	IRCCS Istituto Nazionale Tumori Regina Elena - Roma

Submitted Abstracts

ABSTRACT_8_Digitalpatology in clinical and research

ALTINI NICOLA	Can Generative Adversarial Networks Mitigate the Impact of Small Sample Size in Digital Pathology Setups?	Politecnico di Bari
DE SUMMA SIMONA	Bridging the Gap between Digital Pathology and Molecular Biology: Predicting KRAS Alteration from Whole Slide Images.	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
MELIAU OMBRETTA	Prognostic role of immune content in neuroblastoma: from manual to digital quantification using deep learning predictive method	IRCCS Ospedale Pediatrico Bambino Gesù - Roma
PICCININI FILIPPO	CometAnalyser: a user-friendly open-source deep learning microscopy tool for quantitative comet assay analysis.	IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - Meldola
NACCHIA ANTONIO	Cancer and disease specific survival in patients with bladder cancer treated with radical cystectomy: development of the Cancer Risk Assessment Bladder (CRAB) nomogram	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
DI SOMMA MASSIMO DANTE	Clinical significance of BCMA immunohistochemical expression by bone marrow plasma cells in multiple myeloma.	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
BOVE SAMANTHA	Sentinel Lymph Node Metastasis on Clinically Negative Patients: Preliminary Results of a Machine Learning Model Based on Histopathological Features	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari

ABSTRACT_9_Functional and clinical imaging

CARLONI GIANLUCA	Integrating MRI-radiomics and clinical data for outcome prediction in NSCLC patients treated for brain metastases with SRS	Istituto Europeo di Oncologia - Milano
CARLONI GIANLUCA	Features robustness in the radiomic workflow: the impact of software choice on feature variability	Istituto Europeo di Oncologia - Milano
PLACIDI LORENZO	A Multi-Centre Evaluation of Dosimetrics Features Reproducibility, Stability and Sensitivity	Fondazione Policlinico Universitario A. Gemelli IRCCS - Roma
PESAPANE FILIPPO	Radiomics of MRI for prediction of pathological response to neoadjuvant chemotherapy in breast cancer: a single referral centre analysis	Istituto Europeo di Oncologia - Milano

Submitted Abstracts

TRAVAINI LAURA LAVINIA	Prognostic role of 18F-FDG PET/CT radiomics in Diffuse Large B-Cell Lymphoma patients	Istituto Europeo di Oncologia - Milano
ANNUNZIATA SALVATORE	18F-FDG PET/CT radiomics to predict treatment response and prognosis in Hodgkin lymphoma: a large monocentric study	Fondazione Policlinico Universitario A. Gemelli IRCCS - Roma
GIAJ LEVRA NICCOLO'	Preliminary report of toxicity and quality of life of the first 100 patients treated with 1.5T MR-guided stereotactic body radiotherapy for prostate cancer	IRCCS Ospedale Sacro Cuore Don Calabria - Verona
GIAJ LEVRA NICCOLO'	Impact of hydrogel peri-rectal spacer insertion on seminal vesicles intra-fraction motion during 1.5T-mri-guided adaptive stereotactic body radiotherapy for localized prostate cancer	IRCCS Ospedale Sacro Cuore Don Calabria - Verona
GIAJ LEVRA NICCOLO'	Mitigation on bowel loops daily variations by 1.5-T MR-guided daily-adaptive SBRT for abdomino-pelvic lymph-nodal oligometastases	IRCCS Ospedale Sacro Cuore Don Calabria - Verona
GIAJ LEVRA NICCOLO'	Stereotactic body radiotherapy for oligometastatic castration sensitive prostate cancer using 1.5t mri-linac: preliminary data on feasibility and acute patient-reported outcomes	IRCCS Ospedale Sacro Cuore Don Calabria - Verona
FIGLIA VANESSA	Clinical results of SBRT for spinal metastases using dedicated contouring/planning system	IRCCS Ospedale Sacro Cuore Don Calabria - Verona
FANTI STEFANO	FDG PET/CT imaging and radiomics as predictors of early response in lymphoma patients undergoing CAR T-cell therapy	IRCCS Azienda Ospedaliero- Universitaria di Bologna
COMES MARIA COLOMBA	A transfer learning-based approach on DCE-MRIs to give an early prediction of breast cancer recurrence for patient undergoing neoadjuvant chemotherapy	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
FANIZZI ANNARITA	A Roadmap towards Breast Cancer Therapies Supported by Explainable Artificial Intelligence	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
NACCHIA ANTONIO	Using a machine learning algorithm to predict prostate cancer grade	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
CATINO ANNAMARIA	Clinical parameters and initial therapeutic response in patients with advanced pleural mesothelioma. A perspective for a radiomic-based approach	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari

ABSTRACT_10_Cancer burden, finance, and health-care systems

DE SANCTIS RITA	Success rates of guideline-based supportive care for abemaciclib-induced diarrhoea in advanced breast cancer	IRCCS Humanitas Research Hospital - Milano
-----------------	--	--

Submitted Abstracts

PIGNATA SANDRO	The FORZA project and monitoring training	IRCCS Istituto Nazionale Tumori Fondazione G. Pascale - Napoli
CARACENI AUGUSTO	Multidisciplinary cancer clinics and multidisciplinary team meetings: available models in an Italian Comprehensive cancer Center.	Fondazione IRCCS Istituto Nazionale dei Tumori - Milano
NACCHIA ANTONIO	The role of cutaneous ureterostomy diversion: a multicenter analysis.	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
MAURMO LEONARDA	The Istituto Tumori of Bari Molecular Tumor Board: a new ally of precision medicine	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
ZACCARIA GIAN MARIA	ARGO, Automatic Record Generator for Oncology: a tool to automatically generate eCRFs from real-life pathology reports.	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
TINI GIULIA	A novel index to measure geographical accessibility to cancer clinical trials in different income landscapes	Istituto Europeo di Oncologia - Milano
PINTO MONICA	Cancer prevalence and rehabilitation treatments for Italian cancer patients in 2019: can we do better ?	IRCCS Istituto Nazionale Tumori Fondazione G. Pascale - Napoli
PETRUZZI ALESSANDRA	Neurocognitive functioning and quality of life in glioblastoma long- term survivors	Fondazione IRCCS Istituto Neurologico Carlo Besta
MARELLI LUCA	The ACC-GDPR Committee guidelines: A template for the implementation of the EU GDPR for Italian research hospitals	Istituto Europeo di Oncologia - Milano
NACCHIA ANTONIO	Overall Adverse events of drugs for metastatic renal cell carcinoma: real world reporting patterns from eudra vigilance database	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
NACCHIA ANTONIO	The eortc quality of life questionnaire predicts long-term overall survival in patients treated with robotic assisted radical prostatectomy: analysis of a large single center cohort.	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
NACCHIA ANTONIO	Comparison of Adjuvant Radiotherapy vs Salvage Radiotherapy in patients treated with Radical Prostatectomy: A Systematic Review and Meta-Analysis	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
FANIZZI ANANRITA	Breast Conservation Therapy vs Mastectomy on Disease Free Survival for patients with T1/2 breast cancer and no lymph node metastases: our experience.	IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
NACCHIA ANTONIO	Complications of Intra-Corporeal vs Extra-Corporeal Urinary Diversion in patients treated with laparoscopic radical cystectomy	IRCCS CROB - Centro di Riferimento Oncologico della Basilicata - Rionero in Vulture
SERRA PATRIZIA	Creation of an Integrative Medicine pathway in a cancer research and treatment center	IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - Meldola

Conference venue

The conference will be organized at **The Nicolaus Hotel**, an elegant conference center and hotel which takes place few steps away Bari center in the heart of the Poggiofranco district, with its impressive and monumental beauty.

The Nicolaus hotel

Address - Via C.A. Ciasca 27, 70124 - Bari

Phone - +39 080 5682111

Fax - +39 080 5042058

Email - info@nicolaushotel.com

HOW TO REACH to Bari

By plane.

Connections to the airport of Bari-Palese (10 km of the city center) are provided by domestic flights from the international airports of Rome Fiumicino, Milan Malpensa or Milan Linate.

By train.

At the central station of Bari (Bari Centrale) arrive long-distance express trains (Eurostar(ES) from Rome and Milan in the north, and Brindisi/Lecce in the South.

By car.

On the highway (autostrada) no. A14 from north (direction Foggia, Pescara) or from south (direction Taranto). From Brindisi on the expressway E55.

By bus.

Long-distance bus connections exist to Rome, Sicily, and Germany.

HOW TO REACH conference venue From Bari's airport "Karol Wojtyła"

By car

SS16 BIS to Brindisi

Exit 11 "Poggiofranco" of the bypass of Bari

Follow the road signs "THE NICOLAUS HOTEL"

Public Transport

Subway to Stazione Centrale (central station)

Then Bus AMTAB linea 6 - stop Via Matarrese

Or

Shuttle Bus "Tempesta" to Stazione Centrale (central station)

Then AMTAB linea 6 - stop Via Matarrese

Or Taxi (+39 0805543333)

FROM A14 ADRIATIC HIGHWAY

From North

Exit Bari NORD

Direction Bari tangenziale

Exit SS16 BRINDISI - LECCE

Exit 11 "Poggiofranco" of the bypass of Bari

Follow the road signs "THE NICOLAUS HOTEL"

From South

Exit BARI SUD (the only exit for Bari)

Direction Bari tangenziale

Exit SS16 BRINDISI - TARANTO

Exit 11 "Poggiofranco" of the bypass of Bari

Follow the road signs "THE NICOLAUS HOTEL"

FROM BARI CENTRAL RAILWAY STATION

Taxi in P.zza Moro in front of the central railway station

Or

Bus - Linea Urbana AMTAB in P.zza Moro in front of the central railway station

Bus Linea n° 6 - Stop Via Matarrese

Bus Linea n° 10 - Stop Via Matarrese

Bus Linea D - Stop Via Camillo Rosalba

Flat rates

By Taxi

From the central railway station to the hotel: average price € 10,00

From the airport to the hotel: average price € 25,00

General Informations

Working Language

The official language of the congress will be English.

Badges

Upon registration you will receive your personal envelope containing your badge. All participants, accompanying persons and exhibitors are kindly requested to wear their badges throughout the congress in order to be admitted to the scientific sessions and other scheduled activities.

C.M.E.

The Italian National Accreditation Commission for Continuing Medical Education has granted No **6 credits** for all health disciplines. The Credit certificates shall only be issued if the participant has successfully attended the whole meeting and his/her professional qualifications comply with those required for entitlement to the study credits in question. The **C.M.E.** credit certificate will only be issued after the participant has completed and returned the assessment questionnaire at the end of the webinar.

For any further information please visit

www.meetingacc2021-irccsbari.it



The largest Italian network for cancer research

allianceagainstcancer.org | alleanzacontroilcancro.it